Literature DB >> 16336976

Interleukin-6 decreases senescence and increases telomerase activity in malignant human cholangiocytes.

Yoko Yamagiwa1, Fanyin Meng, Tushar Patel.   

Abstract

BACKGROUND/AIMS: Cellular senescence results in irreversible growth arrest. In malignant cells, senescence is prevented by maintenance of chromosomal length by telomerase activity. Telomerase activity is increased in malignant, but not in normal cholangiocytes. Interleukin-6 (IL-6) is an autocrine promoter of cholangiocarcinoma growth. Our aims were to assess the relationship between IL-6 activated p38 mitogen-activated protein kinase (MAPK) pathways and senescence in malignant cholangiocytes.
METHODS: Cell senescence and telomerase activity was assessed in Mz-ChA-1 malignant human cholangiocytes. The effect of inhibitors of p38 MAPK and telomerase activity on cell proliferation was assessed, and the interaction between these inhibitors was quantitated by median effects analysis.
RESULTS: Mz-ChA-1 cells rapidly underwent senescence during repeated passaging. IL-6 increased telomerase activity and decreased cellular senescence during repeated passaging. However, basal telomerase activity was increased by inhibition of p38 MAPK. Inhibition of telomerase activity decreased IL-6 induced proliferation and had a synergistic effect with p38 MAPK inhibitors. Thus, IL-6 increases telomerase activity independent of p38 MAPK signaling and maintenance of telomerase activity promotes cholangiocarcinoma growth.
CONCLUSION: Enhanced telomerase activity in response to IL-6 stimulation can prevent cellular senescence and thereby contribute to cholangiocarcinoma growth. Inhibition of telomerase activity may therefore be therapeutically useful in biliary tract malignancies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336976      PMCID: PMC1524874          DOI: 10.1016/j.lfs.2005.10.015

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  46 in total

Review 1.  Cholangiocarcinoma: current concepts and insights.

Authors:  Gregory J Gores
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

Review 2.  Telomerases.

Authors:  E H Blackburn
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

Review 3.  Telomere loss: mitotic clock or genetic time bomb?

Authors:  C B Harley
Journal:  Mutat Res       Date:  1991 Mar-Nov       Impact factor: 2.433

4.  Identification of a specific telomere terminal transferase activity in Tetrahymena extracts.

Authors:  C W Greider; E H Blackburn
Journal:  Cell       Date:  1985-12       Impact factor: 41.582

5.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

6.  Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Authors:  Masaharu Akiyama; Teru Hideshima; Toshiaki Hayashi; Yu-Tzu Tai; Constantine S Mitsiades; Nicholas Mitsiades; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

7.  Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro.

Authors:  K Matsumoto; H Fujii; G Michalopoulos; J J Fung; A J Demetris
Journal:  Hepatology       Date:  1994-08       Impact factor: 17.425

8.  Specific association of human telomerase activity with immortal cells and cancer.

Authors:  N W Kim; M A Piatyszek; K R Prowse; C B Harley; M D West; P L Ho; G M Coviello; W E Wright; S L Weinrich; J W Shay
Journal:  Science       Date:  1994-12-23       Impact factor: 47.728

9.  Translational regulation by p38 mitogen-activated protein kinase signaling during human cholangiocarcinoma growth.

Authors:  Yoko Yamagiwa; Carla Marienfeld; Laura Tadlock; Tushar Patel
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

10.  Worldwide trends in mortality from biliary tract malignancies.

Authors:  Tushar Patel
Journal:  BMC Cancer       Date:  2002-05-03       Impact factor: 4.430

View more
  22 in total

1.  Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer.

Authors:  Christopher Johnson; Yuyan Han; Nathan Hughart; Jennifer McCarra; Gianfranco Alpini; Fanyin Meng
Journal:  Transl Gastrointest Cancer       Date:  2012-04-01

Review 2.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

3.  Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway.

Authors:  Jeng-Jer Shieh; Chun-Ying Wu; Sin-Ting Wang; Shi-Wei Huang; Kuang-Ting Liu; Teng-Yu Lee
Journal:  Cell Death Discov       Date:  2020-03-30

4.  Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways.

Authors:  Peter J Naus; Roger Henson; Grant Bleeker; Hania Wehbe; Fanyin Meng; Tushar Patel
Journal:  J Hepatol       Date:  2006-10-06       Impact factor: 25.083

Review 5.  Environmental immune disruptors, inflammation and cancer risk.

Authors:  Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 6.  The effect of environmental chemicals on the tumor microenvironment.

Authors:  Stephanie C Casey; Monica Vaccari; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Mary Helen Barcellos-Hoff; Dustin G Brown; Marion Chapellier; Joseph Christopher; Colleen S Curran; Stefano Forte; Roslida A Hamid; Petr Heneberg; Daniel C Koch; P K Krishnakumar; Ezio Laconi; Veronique Maguer-Satta; Fabio Marongiu; Lorenzo Memeo; Chiara Mondello; Jayadev Raju; Jesse Roman; Rabindra Roy; Elizabeth P Ryan; Sandra Ryeom; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Laura Soucek; Louis Vermeulen; Jonathan R Whitfield; Jordan Woodrick; Annamaria Colacci; William H Bisson; Dean W Felsher
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

7.  Aberrant DNA methylation profile in cholangiocarcinoma.

Authors:  Li Huang; Gabriel Frampton; Li-Jian Liang; Sharon Demorrow
Journal:  World J Gastrointest Pathophysiol       Date:  2010-06-15

Review 8.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

9.  Adverse childhood experiences and leukocyte telomere maintenance in depressed and healthy adults.

Authors:  Stephen H Chen; Elissa S Epel; Synthia H Mellon; Jue Lin; Victor I Reus; Rebecca Rosser; Eve Kupferman; Heather Burke; Laura Mahan; Elizabeth H Blackburn; Owen M Wolkowitz
Journal:  J Affect Disord       Date:  2014-08-05       Impact factor: 4.839

10.  Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis.

Authors:  Qunzhou Zhang; Takayoshi Yamaza; A Paul Kelly; Shihong Shi; Songlin Wang; Jimmy Brown; Lina Wang; Samuel W French; Songtao Shi; Anh D Le
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.